| | | | |

Mesothelioma Survival Improves with Post-Surgery Radiation

Pleural mesothelioma patients who undergo radiotherapy after their surgery tend to live longer than those whose treatment plan does not include radiation.

Unfortunately, only a small percentage of patients who could stand to benefit from this treatment actually get it.

Researchers at Houston Methodist Hospital, Baylor, and The University of Texas have come to that conclusion after analyzing data from the National Cancer Database on nearly 25,000 patients with malignant pleural mesothelioma from 2004 to 2013.

It was the largest study of adjuvant radiotherapy for mesothelioma ever conducted.

Radiotherapy in Mesothelioma Treatment

Although radiotherapy is not routinely used in mesothelioma treatment, when it is used, it is typically either palliative as a way to relieve symptoms, or as an add-on (adjuvant) treatment after surgery.

The idea behind adjuvant radiotherapy is to prevent the seeding of new mesothelioma tumors by destroying any mesothelioma cells that might have been left behind after surgery. This is particularly critical with mesothelioma, which tends to grow and spread quickly.

The new Texas study focused on adjuvant radiotherapy in mesothelioma patients who underwent either extrapleural pneumonectomy (EPP) or lung-sparing pleurectomy with decortication (PD) surgery. A third group that had neither therapy was included as a baseline reference.

Survival Higher in Radiotherapy Patients

To assess the impact of radiotherapy on survival, the research team divided pleural mesothelioma patients into two groups – those who only had surgery and those who had surgery followed by adjuvant radiotherapy.

After accounting for other variables associated with mesothelioma survival, the researchers found that adjuvant radiotherapy increased the odds that a patient would still be alive more than a year after surgery.

“In the whole cohort, the surgery plus radiotherapy group had a higher median survival (21.4 months) compared to surgery alone (16.59 months).” writes lead author and radiation oncologist Gary Lewis, MD, of the University of Texas Medical Branch. The mesothelioma patients who had neither type of intervention had an overall survival rate of just 7.5 months.

Study Points to Need for More Research, Better Access

Although there appeared to be a clear advantage to undergoing both surgery and radiation, the researchers found that only 3 percent of pleural mesothelioma patients were actually treated this way.

Having a tumor confined to one region of the chest, having few other health problems, and having private insurance and/or higher income raised the chances that a patient would receive adjuvant radiotherapy. It was used more often in mesothelioma patients who underwent the more radical EPP surgery than it was in those who had PD.

Patients who received adjuvant radiotherapy were also more likely to receive chemotherapy, which also had a positive impact on their survival.

After two years, nearly 43 percent of patients who had had both surgery and radiotherapy were still alive while only 16.6 percent of the no-local-treatment group were living.

Researchers say the study points to the need for more data on the use of adjuvant radiotherapy in the treatment of the asbestos cancer.

“In the treatment of malignant pleural mesothelioma, adjuvant radiotherapy after surgical intervention was associated with improved overall survival,” the team writes. “Our findings highlight the need for additional prospective data.”\

Source:

Lewis, Gary, et al, “The Role of Adjuvant Radiotherapy in the Treatment of Pleural Mesothelioma, June 1, 2018, International Journal of Radiation Oncology, Volume 101, Issue 2, Supplement, p. E34

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…